New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy TRENDS IN IMMUNOLOGY Houot, R., Kohrt, H. E., Marabelle, A., Levy, R. 2011; 32 (11): 510-516Abstract
Monoclonal antibodies (mAbs) are in widespread use for the treatment of cancer. Their success as cancer therapeutics relies substantially on their ability to engage the immune system. Specifically, Fc-receptor-expressing immune cells mediate the killing of tumor cells by mAbs. Stimulation of these immune effector cells might therefore represent a promising strategy to enhance the therapeutic potential of mAbs. For instance, stimulation of natural killer cells, ?d T cells, macrophages, or dendritic cells can be used to enhance antibody-dependent cellular cytotoxicity, phagocytosis or even tumor vaccine effects. Here, we review several ways to improve the antitumor efficacy of mAbs by combining them with therapies that are directed against immune effector cells.
View details for DOI 10.1016/j.it.2011.07.003
View details for Web of Science ID 000296828400002
View details for PubMedID 21907000